{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:33:40Z","timestamp":1772825620193,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ahj.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T09:50:36Z","timestamp":1554976236000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF"],"prefix":"10.1016","volume":"213","author":[{"given":"Sylvia","family":"Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A John","family":"Camm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bassand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Cools","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Corbalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo G","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Misselwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizaveta","family":"Panchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany Ibrahim","family":"Ragy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina","family":"Stepinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander GG","family":"Turpie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitendra PS","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toon Wei","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Virdone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freek WA","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ahj.2019.03.013_bb0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ahj.2019.03.013_bb0010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.STR.27.10.1765","article-title":"Acute stroke with atrial fibrillation. The Copenhagen Stroke Study","volume":"27","author":"Jorgensen","year":"1996","journal-title":"Stroke"},{"issue":"23","key":"10.1016\/j.ahj.2019.03.013_bb0015","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ahj.2019.03.013_bb0020","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.ahj.2019.03.013_bb0025","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ahj.2019.03.013_bb0030","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","volume":"78","year":"2014","journal-title":"Circ J"},{"issue":"9921","key":"10.1016\/j.ahj.2019.03.013_bb0035","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ahj.2019.03.013_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001798","article-title":"Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study","volume":"4","author":"Lauffenburger","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ahj.2019.03.013_bb0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jth.12845","article-title":"Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study","volume":"13","author":"Gorst-Rasmussen","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ahj.2019.03.013_bb0050","first-page":"1087","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ahj.2019.03.013_bb0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bjorck","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2019.03.013_bb0060","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II","volume":"128","author":"Huisman","year":"2015","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.ahj.2019.03.013_bb0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","article-title":"Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation","volume":"103","author":"Camm","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2019.03.013_bb0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2019.03.013_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.03.013_bb0080","first-page":"114","article-title":"Evolving quality standards for large-scale registries: the GARFIELD-AF experience","volume":"3","author":"Fox","year":"2017","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"10.1016\/j.ahj.2019.03.013_bb0085","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2019.03.013_bb0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.03.013_bb0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.03.013_bb0100","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2019.03.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018905","article-title":"Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry","volume":"8","author":"Apenteng","year":"2018","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ahj.2019.03.013_bb0110","first-page":"1047","article-title":"The disconnect between novel oral anticoagulant eligibility and provincial drug coverage: an Albertan anticoagulation clinic audit","volume":"31","author":"Dhillon","year":"2015","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2019.03.013_bb0115","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.hlc.2018.03.010","article-title":"NOACs now mainstream for the use of anticoagulation in non-valvular atrial fibrillation in Australia","volume":"28","author":"Pol","year":"2018","journal-title":"Heart Lung Circ"},{"issue":"11","key":"10.1016\/j.ahj.2019.03.013_bb0120","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.clinthera.2015.09.008","article-title":"Trends in prescribing oral anticoagulants in Canada, 2008-2014","volume":"37","author":"Weitz","year":"2015","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.ahj.2019.03.013_bb0125","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.13150","article-title":"Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis","volume":"83","author":"Komen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ahj.2019.03.013_bb0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40266-017-0476-4","article-title":"Prescription patterns of non\u2013vitamin K oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012-2015: a study from the Norwegian prescription database","volume":"34","author":"Urbaniak","year":"2017","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.ahj.2019.03.013_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/europace\/euu225","article-title":"Non\u2013vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013","volume":"17","author":"Olesen","year":"2015","journal-title":"Europace"},{"issue":"16","key":"10.1016\/j.ahj.2019.03.013_bb0140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.ahj.2019.03.013_bb0145","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ahj.2019.03.013_bb0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hjdsi.2017.09.004","article-title":"Patterns and predictors of physician adoption of new cardiovascular drugs","volume":"6","author":"Anderson","year":"2018","journal-title":"Healthcare (Amst)"},{"issue":"7","key":"10.1016\/j.ahj.2019.03.013_bb0155","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MLR.0000000000000549","article-title":"Who were the early adopters of dabigatran? An application of group-based trajectory models","volume":"54","author":"Lo-Ciganic","year":"2016","journal-title":"Med Care"},{"issue":"17","key":"10.1016\/j.ahj.2019.03.013_bb0160","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJM199410273311707","article-title":"Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction","volume":"331","author":"Ayanian","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2019.03.013_bb0165","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s11096-015-0174-4","article-title":"Trends in antithrombotic drug use and adherence to non\u2013vitamin K oral anticoagulants in the Netherlands","volume":"37","author":"Hanemaaijer","year":"2015","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"10.1016\/j.ahj.2019.03.013_bb0170","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/europace\/euv242","article-title":"Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings","volume":"18","author":"Mikkelsen","year":"2016","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.ahj.2019.03.013_bb0175","first-page":"747","article-title":"Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention","volume":"32","author":"Andrade","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2019.03.013_bb0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/PPA.S131158","article-title":"Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation","volume":"12","author":"Benzimra","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ahj.2019.03.013_bb0185","first-page":"Cd008600","article-title":"Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation","volume":"4","author":"Clarkesmith","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ahj.2019.03.013_bb0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jval.2016.01.001","article-title":"Physician and patient preferences for nonvalvular atrial fibrillation therapies","volume":"19","author":"Shafrin","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.ahj.2019.03.013_bb0195","first-page":"Cd003839","article-title":"Self-monitoring and self-management of oral anticoagulation","volume":"7","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ahj.2019.03.013_bb0200","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00228-017-2305-4","article-title":"Dabigatran and vitamin K antagonists' use in naive patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records","volume":"73","author":"Vlacho","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ahj.2019.03.013_bb0205","first-page":"1165","article-title":"Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices","volume":"29","author":"Cairns","year":"2013","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2019.03.013_bb0210","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/ijs.12289","article-title":"Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe\u2014a multicentric evaluation","volume":"9","author":"Luger","year":"2014","journal-title":"Int J Stroke"},{"issue":"6","key":"10.1016\/j.ahj.2019.03.013_bb0215","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/phar.2089","article-title":"Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage","volume":"38","author":"Shendre","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"19","key":"10.1016\/j.ahj.2019.03.013_bb0220","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.ahj.2019.03.013_bb0225","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2019.03.013_bb0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ahj.2019.03.013_bb0235","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"S 01","key":"10.1016\/j.ahj.2019.03.013_bb0240","doi-asserted-by":"crossref","first-page":"S 12","DOI":"10.1055\/s-0038-1636530","article-title":"Rivaroxaban: a new treatment paradigm in the setting of vascular protection?","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ahj.2019.03.013_bb0245","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/0003319713486014","article-title":"Protecting the brain and the heart: antithrombotic treatment in nonvalvular atrial fibrillation","volume":"65","author":"Safouris","year":"2014","journal-title":"Angiology"},{"issue":"6","key":"10.1016\/j.ahj.2019.03.013_bb0250","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/eurheartj\/ehx730","article-title":"Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry","volume":"39","author":"Verheugt","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.03.013_bb0255","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2147\/TCRM.S171346","article-title":"Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy","volume":"14","author":"Guerriero","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.ahj.2019.03.013_bb0260","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/bcp.13474","article-title":"Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice","volume":"84","author":"Jobski","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ahj.2019.03.013_bb0265","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/pds.4333","article-title":"Patterns of long-term use of non\u2013vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study","volume":"26","author":"Douros","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.ahj.2019.03.013_bb0270","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/jgs.15058","article-title":"Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults","volume":"65","author":"Fohtung","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.ahj.2019.03.013_bb0275","first-page":"1462","article-title":"Which factors influence resident physicians to prescribe NOACs to patients with non-valvular atrial fibrillation?","volume":"9","author":"Oqab","year":"2016","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.ahj.2019.03.013_bb0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ahj.2017.03.024","article-title":"Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)","volume":"189","author":"Steinberg","year":"2017","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319300791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:56Z","timestamp":1762077416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319300791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":56,"alternative-id":["S0002870319300791"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.03.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}